undamentalytics Newsletter
Sign in

Glaukos Corp (GKOS) stock

Add to watchlist

Add holding +

NYSE: GKOS NYSE Health Care Equipment Next results ~January 20, 2027

C+ Fundamentals grade

Glaukos Corp is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$49

Revenue-to-maturity model

Base case. Range ~$40–$59. Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Glaukos Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 8 selling0 purchases and 61 sales by directors and officers, last 12 monthsInsider trades
  • Funds212 adding, 141 cuttingOf 68 active managers that changed their stake, 37 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Glaukos files

Where Glaukos stands after its latest 10-Q

Revenue for the twelve months to September 2026 was $690m, up 46.9% on a year earlier, faster than the 41.5% growth a quarter earlier. That growth ranks 2 of 58 among the health care equipment companies we cover. Free-cash-flow margin rose to 5.2% from -5.9% a year earlier. Operating margin narrowed to -25.5% from -18.8%. The diluted share count is up 3.8% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 3 financial-health checks. Our revenue-to-maturity cash-flow model value is $49.78 a share, against a share price of $240.

Source: 10-Q filed October 28, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 20, 2027 (estimated)

Glaukos Corp's trailing-twelve-month revenue grew 46.9% year on year, with a free-cash-flow margin of 5.2%. Where it stands out: revenue growth of 46.9% ranks 14 of 129 health care equipment companies we cover.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 619% in the quarter to 2026-09-30, the 3rd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 46.9% over the last 12 months, against a median of 9.1% for health care equipment companies we cover.
  • Growth speeding up. The growth rate is 5.4 points higher than a quarter earlier.
  • Net cash. Cash exceeds long-term debt by $0.2bn.
  • Estimates rising. Analysts' consensus for next year's earnings per share has risen 108.6% over 90 days.

Things to watch

  • Loss-making. Operating margin is -25.5%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 6.7 points on a year ago.
  • Share dilution. Diluted shares rose 3.8% in a year.
  • High sales multiple. The shares trade at 20 times revenue while operating margins remain thin.
  • Volatile shares. Over the past year the shares showed annualised volatility of 60% and a beta of 0.8 against the S&P 500.
  • Insiders selling. 8 insiders sold $69M of stock over the past 365 days and none bought (68% under pre-set trading plans).

Latest results: FY2026 Q3

Filed October 28, 2026
Earnings per share
$0.47 against an average estimate of -$0.09: beat by 618.7%
Revenue
$211m, up 58.0% on a year earlier
Share reaction
+33.8% in the first session after the results on October 28, 2026, against 0.0% for the S&P 500
Guidance given
net sales $775m to $785m (2026); net sales $1bn (2027)
Next report
October 28, 2026; average EPS estimate $0.38

Glaukos' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.4%
  • 1 week+33.8%
  • 1 month+45.7%
  • This year+111.3%
  • 1 year+170.9%
  • 5 years+346.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$690M
Operating margin
-25.5%
Net margin
-24.6%
EPS (TTM, diluted)
$-2.88

Growth

Revenue growth
+46.9%
Change in growth rate
+5.4 pts
Share count change
+3.8%

Cash

Free cash flow (TTM)
$36M
FCF margin
5.2%
Stock pay % of revenue
12.0%

Earnings

Last results
October 28, 2026
Next results (est.)
January 20, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Guidance
  3. Insider trade
  4. Insider trade
  5. Announcement
  6. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Glaukos Corp valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Glaukos Corp as an operating company, with every model that fits that kind of business. Cost of equity 9.4%: the 10-year Treasury yield (4.9%) plus a beta of 0.98 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$21 ~$12–$30 Left out: out of range vs price (0.09x)
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$17 ~$15–$27 Left out: out of range vs price (0.07x)
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$21 ~$22–$78 Left out: out of range vs price (0.09x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$49 ~$40–$59 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$49 ~$40–$59 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Glaukos Corp with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$24.69$34.30$25.65$56.17$54.47$75.26$44.44$43.68$79.49$149.94$112.91$238.61
Market value$863m$1.3bn$882m$2.0bn$2.2bn$3.3bn$2.1bn$2.1bn$3.8bn$7.9bn$6.5bn$14.1bn
+ Net debt (− = net cash)−$12m−$3m−$25m−$30m−$62m$93m$179m$162m$189m−$113m−$91m−$162m
Enterprise value$851m$1.2bn$857m$2.0bn$2.2bn$3.4bn$2.2bn$2.2bn$4.0bn$7.8bn$6.4bn$13.9bn
Multiples
Price / sales 12.0x10.9x5.5x10.9x9.5x14.9x7.0x7.3x12.2x20.6x12.7x20.4x
Price / earnings —n/m——145.3x———————
Price / free cash flow —n/m44.6xn/m———————n/m
EV / EBITDA —139.1xn/m—————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

28 /100

Weak moat

How hard Glaukos's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median 1.9% of total assets over 10 years.

  • Pricing power 14 / 20

    Gross margin has been a median 76.5%, moving by 8.5 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -18.4%; its worst year was -40.8%.

  • Cash conversion 4 / 20

    Free cash flow was positive in 4 of 10 years, at a median -3.0% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 26.3% over five years; stock-based pay has been a median 13.1% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.61 +168% $781m +54%
Next $1.05 +71% $1.0bn +29%

Next year's EPS estimate has moved +108.6% in 90 days, across 13 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −310.6% on 90 days ago. In the last 30 days, 12 analysts raised Glaukos Corp's forecast and 0 cut it.

Consensus EPS forecast Glaukos Corp, last 90 days
−$0.50 $0.00 $0.50 $1.00 $1.50 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.29 Current fiscal year, 60 days ago: −$0.29 Current fiscal year, 30 days ago: −$0.29 Current fiscal year, 7 days ago: −$0.30 Current fiscal year, Now: $0.61 $0.61 Next fiscal year, 90 days ago: $0.50 Next fiscal year, 60 days ago: $0.50 Next fiscal year, 30 days ago: $0.51 Next fiscal year, 7 days ago: $0.52 Next fiscal year, Now: $1.05 $1.05

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.29$0.50
60 days ago −$0.29$0.50
30 days ago −$0.29$0.51
7 days ago −$0.30$0.52
Now $0.61$1.05

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 −$0.09 $0.47 +618.7%
Jun 2026 −$0.21 −$0.14 +33.5%
Mar 2026 −$0.28 −$0.18 +35.9%
Dec 2025 −$0.20 −$0.28 −43.2%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 28, 2026
  • net sales 2026 $775m to $785m Raised
    “Raised 2026 net sales guidance to $775 million to $785 million, compared to $680 million to $700 million previously.” source
  • net sales 2027 about $1bn New
    “Introduced preliminary 2027 net sales guidance of $1 billion.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

13 analysts, Oct 2026
Buy1292%
Hold18%
Sell00%

Monthly trend

  1. Oct 202639113
  2. Sep 2026310114
  3. Aug 2026310114
  4. Jul 2026310114

Counts of recommendations published by analysts covering Glaukos Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
8.9%
of tradable shares
Days to cover
4.37
at average volume
Short interest, 1 month
+4%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
3.6%
of shares
Employees
1,094
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +170.9%

$88.07 on October 31, 2025 to $238.61

ThenNowEffect
Revenue (last 12 months) $433m $613m +41.5%
P/S multiple 11.4x 22.6x +97.5%
Share count 56m 58m −3.1%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +271.6%

$64.21 on November 3, 2023 to $238.61

ThenNowEffect
Revenue (last 12 months) $297m $613m +106.5%
P/S multiple 10.2x 22.6x +120.6%
Share count 47m 58m −18.4%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
GKOS−41%−2%+82%+89%−25%+111%
Industry peers (median)−7%−37%−9%−20%−16%−15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
GKOS50%58%58%75%58%73%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
GKOS−59%−45%−25%−13%−54%−28%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 70% from August 1, 2019 to March 20, 2020. Getting back needed a 229% gain, reached on January 13, 2021, 299 days after the low.

Price behaviour

52-week range
$81.79 – $242.48
From 52-week high
−1.6%
vs 50-day average
+36.8%
vs 200-day average
+67.9%
Volatility (1 year)
60%
Beta vs S&P 500
0.81

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±12.3%
After a week
7 up, 4 down
typical move ±10.4%
After a month
7 up, 4 down
typical move ±14.0%
Results releasedNext dayS&P 500 next day5 days21 days
October 28, 2026 +33.8% 0.0% — —
July 29, 2026 +11.4% +0.1% +13.0% +20.2%
April 29, 2026 +20.1% +1.0% +13.1% −13.6%
February 17, 2026 +10.5% +0.7% +8.9% −5.7%
January 13, 2026 −5.8% −0.7% +11.9% −3.8%
October 29, 2025 +12.9% −1.1% +8.4% +36.6%
July 30, 2025 −8.2% −0.5% −5.6% +3.0%
April 30, 2025 −11.0% +0.7% −6.0% +0.5%
February 20, 2025 −21.6% −2.1% −26.3% −36.3%
November 4, 2024 −3.0% +1.0% +8.6% +4.9%
July 31, 2024 −0.2% +0.2% −1.7% +12.5%
May 1, 2024 +9.4% +0.6% +11.4% +17.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Glaukos Corp in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Glaukos Corp
$300M $400M $500M $600M $700M FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $314.7M Revenue (TTM), FY24 Q1: $326.4M Revenue (TTM), FY24 Q2: $341.7M Revenue (TTM), FY24 Q3: $360.3M Revenue (TTM), FY24 Q4: $383.5M Revenue (TTM), FY25 Q1: $404.5M Revenue (TTM), FY25 Q2: $433M Revenue (TTM), FY25 Q3: $469.8M Revenue (TTM), FY25 Q4: $507.4M Revenue (TTM), FY26 Q1: $551.3M Revenue (TTM), FY26 Q2: $612.8M Revenue (TTM), FY26 Q3: $690.3M $690.3M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $314.7M
FY24 Q1 $326.4M
FY24 Q2 $341.7M
FY24 Q3 $360.3M
FY24 Q4 $383.5M
FY25 Q1 $404.5M
FY25 Q2 $433M
FY25 Q3 $469.8M
FY25 Q4 $507.4M
FY26 Q1 $551.3M
FY26 Q2 $612.8M
FY26 Q3 $690.3M
Revenue growth, TTM YoY Glaukos Corp
0% 20% 40% 60% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 11.3% Revenue growth, TTM YoY, FY24 Q1: 12.9% Revenue growth, TTM YoY, FY24 Q2: 15.1% Revenue growth, TTM YoY, FY24 Q3: 18.7% Revenue growth, TTM YoY, FY24 Q4: 21.9% Revenue growth, TTM YoY, FY25 Q1: 23.9% Revenue growth, TTM YoY, FY25 Q2: 26.7% Revenue growth, TTM YoY, FY25 Q3: 30.4% Revenue growth, TTM YoY, FY25 Q4: 32.3% Revenue growth, TTM YoY, FY26 Q1: 36.3% Revenue growth, TTM YoY, FY26 Q2: 41.5% Revenue growth, TTM YoY, FY26 Q3: 46.9% 46.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 11.3%
FY24 Q1 12.9%
FY24 Q2 15.1%
FY24 Q3 18.7%
FY24 Q4 21.9%
FY25 Q1 23.9%
FY25 Q2 26.7%
FY25 Q3 30.4%
FY25 Q4 32.3%
FY26 Q1 36.3%
FY26 Q2 41.5%
FY26 Q3 46.9%
Operating margin (TTM) Glaukos Corp
-60% -40% -20% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -40.9% Operating margin (TTM), FY24 Q1: -41.3% Operating margin (TTM), FY24 Q2: -39.7% Operating margin (TTM), FY24 Q3: -36.7% Operating margin (TTM), FY24 Q4: -31.9% Operating margin (TTM), FY25 Q1: -25.7% Operating margin (TTM), FY25 Q2: -22.3% Operating margin (TTM), FY25 Q3: -18.8% Operating margin (TTM), FY25 Q4: -39.3% Operating margin (TTM), FY26 Q1: -36.1% Operating margin (TTM), FY26 Q2: -31.6% Operating margin (TTM), FY26 Q3: -25.5% -25.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -40.9%
FY24 Q1 -41.3%
FY24 Q2 -39.7%
FY24 Q3 -36.7%
FY24 Q4 -31.9%
FY25 Q1 -25.7%
FY25 Q2 -22.3%
FY25 Q3 -18.8%
FY25 Q4 -39.3%
FY26 Q1 -36.1%
FY26 Q2 -31.6%
FY26 Q3 -25.5%
FCF margin (TTM) Glaukos Corp
-30% -20% -10% 0% 10% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: -24.8% FCF margin (TTM), FY24 Q1: -23.0% FCF margin (TTM), FY24 Q2: -23.9% FCF margin (TTM), FY24 Q3: -22.6% FCF margin (TTM), FY24 Q4: -17.6% FCF margin (TTM), FY25 Q1: -13.2% FCF margin (TTM), FY25 Q2: -6.2% FCF margin (TTM), FY25 Q3: -5.9% FCF margin (TTM), FY25 Q4: -4.4% FCF margin (TTM), FY26 Q1: -3.4% FCF margin (TTM), FY26 Q2: -2.0% FCF margin (TTM), FY26 Q3: 5.2% 5.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -24.8%
FY24 Q1 -23.0%
FY24 Q2 -23.9%
FY24 Q3 -22.6%
FY24 Q4 -17.6%
FY25 Q1 -13.2%
FY25 Q2 -6.2%
FY25 Q3 -5.9%
FY25 Q4 -4.4%
FY26 Q1 -3.4%
FY26 Q2 -2.0%
FY26 Q3 5.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 21 46 72 114 159 181 237 225 294 283 315 383 507 690
Gross profit 18 34 59 98 138 156 198 133 227 214 239 289 283 447
EBITDA −13 −9 −6 9 3 −7 −44 −94 −3 −51 −95 −87 −162 −134
Operating income −14 −13 −10 4 −2 −13 −50 −124 −33 −82 −129 −122 −200 −176
Net income −13 −12 −37 5 −0 −13 15 −120 −50 −99 −135 −146 −188 −170
Diluted EPS −$0.39 −$0.33 −$1.06 $0.12 $0.00 −$0.37 $0.37 −$2.70 −$1.07 −$2.09 −$2.78 −$2.77 −$3.28 −$2.88
Growth (year on year)
Revenue — +117.6% +57.3% +59.5% +39.2% +13.8% +30.7% −5.1% +30.7% −3.8% +11.3% +21.9% +32.3% +46.9%
EBITDA — — — — −64.3% −310.5% — — — — — — — —
Operating income — — — — −153.8% — — — — — — — — —
Net income — — — — −102.0% — — −880.3% — — — — — —
Diluted EPS — — — — −100.0% — — −829.7% — — — — — —
Margins
Gross margin 87.9% 75.0% 81.9% 85.9% 86.8% 86.2% 83.7% 59.2% 77.3% 75.6% 76.0% 75.5% 55.7% 64.8%
EBITDA margin −62.3% −19.6% −8.4% 7.8% 2.0% −3.7% −18.6% −41.9% −1.1% −17.9% −30.2% −22.6% −31.8% −19.5%
Operating margin −67.8% −28.9% −14.4% 3.7% −1.4% −7.2% −21.2% −54.9% −11.2% −29.1% −40.9% −31.9% −39.3% −25.5%
Net margin −60.3% −26.6% −51.9% 4.0% −0.1% −7.1% 6.5% −53.5% −16.9% −35.1% −42.8% −38.2% −37.0% −24.6%
Free-cash-flow margin −67.6% −17.5% −4.3% 5.3% 12.4% 4.7% −2.1% −13.3% −7.8% −22.4% −24.8% −17.6% −4.4% 5.2%
Cash flow
Cash from operations −13 −7 −2 12 26 19 −0 −23 25 −33 −58 −61 −15 48
Capital spending 1 1 1 6 6 10 5 7 48 30 20 6 8 12
Free cash flow −14 −8 −3 6 20 9 −5 −30 −23 −63 −78 −68 −22 36
Stock-based pay 1 2 8 9 18 26 36 46 30 39 44 50 63 83
Free cash flow after stock pay −16 −10 −11 −3 2 −17 −41 −76 −53 −102 −122 −118 −86 −47
Balance sheet
Cash 7 2 22 6 25 30 62 97 101 120 93 170 91 162
Total debt 0 19 10 3 0 0 0 189 280 281 283 57 0 0
Net debt (negative = net cash) −7 17 −12 −3 −25 −30 −62 93 179 162 189 −113 −91 −162
Diluted shares 33m 37m 35m 36m 34m 35m 41m 44m 46m 47m 48m 53m 57m 59m
Returned to shareholders
Buybacks 0 — — — — — — — — — — — — —
Total returned 0 — — — — — — — — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · September 30, 2026
What it owns · $980m
Short-term assets $580mLonger-term assets $400m
What it owes, and who funded it · $980m
Short-term liabilities $127mLonger-term liabilities $136mShareholders' equity $717m
  • Short-term assets cover short-term liabilities $580m of assets due within a year against $127m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $580m short-term assets against $136m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$176m against $5m of interest.

From Glaukos Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+3.8%
year over year
R&D spending
29.2%
of revenue
Sales & admin spending
63.0%
of revenue
Days sales outstanding
79 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated GKOS TMDX NVCR MYGN BVS IRTC Median
Revenue, last 12 months $690m $668m $725m $807m $586m $825m $99m
Revenue growth, last 12 months 46.9% 25.8% 12.9% −3.2% 3.9% 25.6% 9.2%
Revenue growth, 3-year average 31.5% 64.2% 12.9% 4.9% 5.2% 22.2% 13.5%
Revenue growth, latest quarter 58.0% 20.7% 15.7% −10.5% 2.7% 20.1% 10.2%
Gross margin 64.8% 58.7% 77.0% 68.8% 68.7% 71.5% 61.2%
Operating margin −25.5% 12.2% −17.2% −12.2% 9.7% −3.0% −8.5%
Operating margin, 3-year average −27.0% 8.8% −24.1% −27.2% 4.4% −14.3% −17.9%
Net margin −24.6% 22.7% −16.8% −14.0% 9.8% −1.7% −12.0%
Cash from operations / revenue 6.9% 21.8% −0.1% 1.0% 14.9% 10.4% −1.9%
Free-cash-flow margin 5.2% 11.8% −3.4% −4.2% 14.5% 4.7% −3.9%
Free-cash-flow margin, 3-year average −7.7% −13.0% −9.0% −10.5% 9.7% −3.0% −7.0%
Stock pay / revenue 12.0% 5.5% 16.2% 3.6% 2.8% 10.1% 6.1%
Change in share count 3.8% 4.8% 3.9% 2.5% 6.2% 2.9% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 46.9% 9.1% 14 of 129
Change in growth rate Growth +5.4pp -0.6pp 23 of 129
Gross margin Profitability 64.8% 61.9% 53 of 123
Operating margin Profitability -25.5% -8.3% 77 of 132
Net margin Profitability -24.6% -12.0% 76 of 133
Free-cash-flow margin Cash generation 5.2% -3.4% 40 of 128
Stock pay as % of revenue Cash generation 12.0% 6.1% 82 of 123
Change in share count Balance sheet 3.8% 3.3% 61 of 115
Days sales outstanding Balance sheet 79 days 57 days 94 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Glaucoma $421M 83.0% ▲ 38.8%
Corneal Health $86.4M 17.0% ▲ 7.7%
Geography
Region Revenue Share YoY
United States $375M 73.9% ▲ 38.9%
Outside the US $132M 26.1% ▲ 16.8%

From Glaukos Corp's 10-K filed February 23, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$8.5B
Institutions reporting
365
Shares held vs prior quarter
▲ 4.9%
Positions opened / closed
65 / 38

Top buyers and sellers, Q2 2026: 212 institutions bought and 141 sold ; the biggest buyer was Fuller & Thaler Asset Management, Inc (+530K shares) and the biggest seller Goldman Sachs Group Inc (−478K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $1.3B 9.5M 15.8% ▲ 5.0%
Jupiter Topco LLC $680M 4.9M 8.0% —
Vanguard Portfolio Management LLC $464M 3.3M 5.5% ▲ 3.5%
Primecap Management Co $425M 3.0M 5.0% ▼ 9.8%
Vanguard Capital Management LLC $357M 2.6M 4.2% ▲ 1.7%
State Street Corp $324M 2.3M 3.8% ▲ 6.1%
Millennium Management LLC $221M 1.6M 2.6% ▲ 34.7%
Holocene Advisors, LP $212M 1.5M 2.5% ▲ 9.5%
Geode Capital Management, LLC $205M 1.5M 2.4% ▲ 7.9%
Citadel Advisors LLC $194M 1.4M 2.3% ▼ 3.9%
Ameriprise Financial Inc $184M 1.3M 2.2% ▼ 18.4%
Capital World Investors $142M 1.0M 1.7% ▲ 2.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Glaukos Corp's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $69.3M 61 trades by 8 insiders · 68% under pre-set plans
Net ▼ $69.3M net selling
Insider Date Trade Shares Price Value
Navratil Tomas CHIEF DEVELOPMENT OFFICER October 5, 2026 Sell pre-set plan 312 $165.60 $51,667
Navratil Tomas CHIEF DEVELOPMENT OFFICER October 5, 2026 Sell pre-set plan 327 $164.78 $53,883
Navratil Tomas CHIEF DEVELOPMENT OFFICER October 5, 2026 Sell pre-set plan 888 $163.93 $145,570
Navratil Tomas CHIEF DEVELOPMENT OFFICER September 25, 2026 Sell pre-set plan 1,083 $154.88 $167,735
Navratil Tomas CHIEF DEVELOPMENT OFFICER September 25, 2026 Sell pre-set plan 229 $154.24 $35,321
Navratil Tomas CHIEF DEVELOPMENT OFFICER September 25, 2026 Sell pre-set plan 136 $152.71 $20,769
Navratil Tomas CHIEF DEVELOPMENT OFFICER September 25, 2026 Sell pre-set plan 167 $151.70 $25,334
Navratil Tomas CHIEF DEVELOPMENT OFFICER September 16, 2026 Sell pre-set plan 460 $167.32 $76,967
Navratil Tomas CHIEF DEVELOPMENT OFFICER September 16, 2026 Sell pre-set plan 234 $170.95 $40,002
Navratil Tomas CHIEF DEVELOPMENT OFFICER September 16, 2026 Sell pre-set plan 120 $168.38 $20,206
Navratil Tomas CHIEF DEVELOPMENT OFFICER September 16, 2026 Sell pre-set plan 4 $172.00 $688
Navratil Tomas CHIEF DEVELOPMENT OFFICER September 16, 2026 Sell pre-set plan 191 $166.20 $31,744

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 20, 2027 estimated from the company's past filing pattern, not announced

  • October 28, 2026
  • July 29, 2026
  • April 29, 2026
  • February 17, 2026
  • January 13, 2026
  • October 29, 2025

Recent SEC filings

Data status

When each part of this page on Glaukos Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Glaukos Corp in brief

What does Glaukos Corp do?
Glaukos Corp is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Glaukos Corp's stock ticker?
Glaukos Corp trades under the ticker GKOS on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Glaukos Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Glaukos Corp reported revenue of $690M, 46.9% higher than a year earlier, according to its SEC filings.
What is Glaukos Corp's free cash flow?
Glaukos Corp's free-cash-flow margin is 5.2% of revenue over the trailing twelve months, ranking 40 of the 128 health care equipment companies we cover.
Who are Glaukos Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Jupiter Topco LLC and Vanguard Portfolio Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Glaukos Corp's market cap?
On November 2, 2026, Glaukos Corp's market capitalisation was about $14.1B and net debt of -$162M. Market figures come from third-party market data and may be delayed.
Who are Glaukos Corp's competitors?
In our Health Care Equipment peer group, the companies closest to Glaukos Corp are Transmedics Group, Inc., Novocure Ltd, Myriad Genetics Inc, Bioventus Inc. and Irhythm Holdings, Inc. The side-by-side comparison below sets their revenue, margins and growth against Glaukos Corp's.
Are insiders buying or selling Glaukos Corp stock?
Over the last 12 months, Glaukos Corp's directors and officers reported 0 open-market purchases and 61 sales on Form 4. The insider trading page charts every trade.
When is Glaukos Corp's next earnings date?
Around January 20, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Glaukos Corp announces its own schedule.